艾力斯 (688578)
Shanghai Allist Pharmaceuticals Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 45000.00
- Circulating A-Shares(W): 45000.00
- Earnings Per Share(RMB): 3.5900
- Net Assets Per Share(RMB): 14.4418
- Operating Revenue(W RMB): 373301.77
- Total Profit(W RMB): 188870.08
- **Net Profit Attributable to Parent(W RMB) **: 161577.66
- Net Profit Growth Rate(%): 52.01
- Weighted Return on Equity(%): 27.9200
- Operating Cash Flow Per Share(RMB): 3.8450
- Undistributed Profit Per Share(RMB): 5.4048
- Capital Reserve Per Share(RMB): 7.2873
2. Main Business
The main business covers:
- R&D and sales of innovative drugs in the field of oncology treatment.
3. Company Basic Information
- Company Name: Shanghai Allist Pharmaceuticals Co., Ltd.
- Listing Date: 2020-12-02
- Industry: Pharmaceutical Manufacturing
- Address: 5th Floor, Building 1, No. 1227 Zhangheng Road, No. 1118 Harley Road, China (Shanghai) Pilot Free Trade Zone
- Website: https://www.allist.com.cn
- Company Profile: The company was established through the overall transformation of Shanghai Allist Pharmaceutical Technology Co., Ltd., focusing on the R&D of innovative drugs in the field of oncology treatment, technology transfer, and related consulting services.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Qiaoke Enterprise Development Co., Ltd. | General Legal Person | 14477.68 | 32.17 |
| 2 | Shanghai Aixiang Enterprise Development Center (Limited Partnership) | General Legal Person | 2252.07 | 5.00 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 2094.71 | 4.65 |
| 4 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 859.51 | 1.91 |
| 5 | E Fund SSE STAR Market 50 Constituents ETF | Fund | 828.14 | 1.84 |
| 6 | ChinaAMC SSE STAR Market 50 Constituents ETF | Fund | 796.44 | 1.77 |
| 7 | Morgan Emerging Power Hybrid Securities Investment Fund Class A | Fund | 251.22 | 0.56 |
| 8 | Morgan China Advantage Securities Investment Fund Class A | Fund | 84.72 | 0.19 |
| 9 | ICBC Credit Suisse Strategic Transformation Theme Stock Securities Investment Fund Class A | Fund | 83.09 | 0.18 |
| 10 | Morgan Technology Frontier Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 81.92 | 0.18 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- Heavily Held by Funds
- Hundred-Yuan Stocks
- Non-Cyclical Stocks
- SSE Governance
- SSE 380
- Mid-Cap Growth
- SZSE Growth
- Tencent Ji'an
- STAR Market 50
- Innovation 100
- STAR Market Biotech
- Emerging Market Index
Remarks
- Data update date: 2025-11-04
- Data source: Public Market Information